{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-85","upperLimit":"706","value":"0.0"},{"groupId":"OG001","lowerLimit":"-86","upperLimit":"429","value":"0.0"}]}],"title":"Week 44"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-85","upperLimit":"706","value":"0.0"},{"groupId":"OG001","lowerLimit":"-86","upperLimit":"591","value":"0.0"}]}],"title":"Week 92"}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"37"}],"units":"Participants"}],"description":"The percent change in A1-microglobulin was calculated as \\[Week 44 or 92 A1-microglobulin minus Baseline A1-microglobulin\\] divided by Baseline A1-microglobulin, multiplied by 100. For the Week 44 analysis, the last available value on/before Week 44 was used in the calculation. For the Week 92 analysis, the last available value on/before Week 92 was used in the calculation.","dispersionType":"Full Range","groups":[{"description":"Participants with multiple myeloma received ibandronate via 15-minute IV infusion as 6 mg every 4 weeks for up to 92 weeks. As a result of slow recruitment, the treatment duration was shortened to 40 weeks for participants who had not yet received 48 weeks of treatment. All participants returned for an additional follow-up observation 4 weeks after the end of treatment.","id":"OG000","title":"Ibandronate"},{"description":"Participants with multiple myeloma received zoledronate via 15-minute IV infusion as 4 mg every 4 weeks for up to 92 weeks. As a result of slow recruitment, the treatment duration was shortened to 40 weeks for participants who had not yet received 48 weeks of treatment. All participants returned for an additional follow-up observation 4 weeks after the end of treatment.","id":"OG001","title":"Zoledronate"}],"paramType":"MEDIAN","populationDescription":"ITT Population. The \"Number of Participants Analyzed\" reflects the total number of participants who provided evaluable data for the endpoint.","reportingStatus":"POSTED","timeFrame":"Baseline and Weeks 44, 92","title":"Percent Change From Baseline in Alpha (A) 1-Microglobulin","type":"SECONDARY","unitOfMeasure":"percent change"}